Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Janssen Research & Development, LLC clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
7
Current sort
Recently updated
Sponsor scope
Janssen Research & Development, LLC
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Janssen Research & Development, LLC. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 697–703 of 703 matching trials for sponsor Janssen Research & Development, LLC.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

NCT01508182
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Nov 7, 2026, 12:36 PM EST
Completed Phase 1 Interventional

A Study of Doripenem in Infants Less Than 12 Weeks of Age

NCT01381848
View directory record Official record
Conditions
Bacterial Infections
Interventions
Doripenem
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 12 Weeks
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Little Rock, Arkansas • Orange, California • Royal Oak, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 7, 2026, 12:36 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463774
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: Canagliflozin tablet, Treatment A: Metformin IR tablets, Treatment B: Canagliflozin/metformin fixed dose combination tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Nov 7, 2026, 12:36 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

NCT01463228
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Nov 7, 2026, 12:36 PM EST
Withdrawn Phase 2 Interventional

Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

NCT01362699
View directory record Official record
Conditions
Alcoholism
Interventions
JNJ-31001074, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
21 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Nov 7, 2026, 12:36 PM EST
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Nov 7, 2026, 12:36 PM EST
Terminated Phase 2 Interventional

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

NCT00021723
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AN-1792 also known as AIP-001
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
11
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Nov 7, 2026, 12:36 PM EST

About this Janssen Research & Development, LLC sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Janssen Research & Development, LLC is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Janssen Research & Development, LLC trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Janssen Research & Development, LLC.